Ensysce Biosciences, Inc.
ENSC
$2.17
-$0.30-12.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -61.87% | 1,780.58% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -61.87% | 1,780.58% | |||
| Cost of Revenue | 124.91% | 78.49% | |||
| Gross Profit | -244.60% | 325.79% | |||
| SG&A Expenses | -0.54% | -8.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 75.92% | 29.80% | |||
| Operating Income | -654.75% | 132.97% | |||
| Income Before Tax | -638.59% | 133.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -638.59% | 133.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -638.59% | 133.63% | |||
| EBIT | -654.75% | 132.97% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -388.93% | 129.98% | |||
| Normalized Basic EPS | -388.94% | 129.98% | |||
| EPS Diluted | -388.93% | 129.98% | |||
| Normalized Diluted EPS | -388.94% | 129.98% | |||
| Average Basic Shares Outstanding | 86.40% | 12.18% | |||
| Average Diluted Shares Outstanding | 86.40% | 12.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||